ArcticZymes Technologies
ISIN: NO0010014632 | Ticker: AZT | LEI: 5967007LIEEXZXGR7K47
Country: Norway
ArcticZymes Technologies has a long history dating back to the late 1980s. Based in Tromsø, Northern Norway, we use access to the marine Arctic to identify new cold-adapted enzymes for use in molecular research, in vitro diagnostics and therapeutics. We focus on strong and reliable relationships with our business partners and commercial innovators around the world. Therefore, we are constantly striving to work at the highest level and not only meet but exceed the expectations of our partners.
Our no-compromises approach ensures that our enzymes are robustly and reproducibly manufactured to deliver highly consistent products you can rely on. Our product development, manufacturing, sales and marketing processes are therefore certified and in accordance to the ISO13485 quality standard.
1990
Served areaWorldwide
HeadquartersPostboks 6463, 9294 Tromsø – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|---|
| Assets | N/A | 221,912,000.00 | N/A | 284,111,000.00 | N/A | 319,037,000.00 |
| Noncurrent Assets | N/A | 47,140,000.00 | N/A | 50,692,000.00 | N/A | 49,792,000.00 |
| Property Plant And Equipment | N/A | 3,058,000.00 | N/A | 12,302,000.00 | N/A | 15,444,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 420,000.00 | N/A | 1,790,000.00 | N/A | N/A |
| Other Intangible Assets | N/A | N/A | N/A | 1,790,000.00 | N/A | 9,236,000.00 |
| Deferred Tax Assets | N/A | 33,143,000.00 | N/A | 20,522,000.00 | N/A | 11,239,000.00 |
| Other Noncurrent Assets | N/A | 5,000.00 | N/A | N/A | N/A | N/A |
| Current Assets | N/A | 174,771,000.00 | N/A | 233,420,000.00 | N/A | 269,246,000.00 |
| Inventories | N/A | N/A | N/A | 6,882,000.00 | N/A | 7,078,000.00 |
| Current Trade Receivables | N/A | 10,575,000.00 | N/A | 20,281,000.00 | N/A | N/A |
| Other Current Receivables | N/A | 20,130,000.00 | N/A | 5,833,000.00 | N/A | N/A |
| Cash and cash equivalents | 31,662,000.00 | 140,178,000.00 | N/A | 200,424,000.00 | 200,424,000.00 | 244,161,000.00 |
| Equity And Liabilities | N/A | 221,912,000.00 | N/A | 284,111,000.00 | N/A | 319,037,000.00 |
| Equity | 46,476,000.00 | 196,330,000.00 | 1,010.00 | 31,120.00 | N/A | 31,120.00 |
| Issued Capital | N/A | 48,335,000.00 | N/A | 50,371,000.00 | N/A | 50,571,000.00 |
| Share Premium | N/A | 151,039,000.00 | N/A | 260,256,000.00 | N/A | 261,656,000.00 |
| Additional Paidin Capital | N/A | N/A | N/A | 111,100,000.00 | N/A | N/A |
| Equity Attributable To Owners Of Parent | N/A | N/A | N/A | 244,845,000.00 | N/A | 284,736,000.00 |
| Noncontrolling Interests | N/A | 1,966,000.00 | N/A | N/A | N/A | N/A |
| Liabilities | N/A | 25,582,000.00 | N/A | 39,266,000.00 | N/A | 34,301,000.00 |
| Noncurrent Liabilities | N/A | 9,595,000.00 | N/A | 14,472,000.00 | N/A | 10,348,000.00 |
| Current Liabilities | N/A | 15,987,000.00 | N/A | 24,794,000.00 | N/A | 23,953,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 3,456,000.00 | N/A | 5,795,000.00 | N/A | N/A |
| Current Dividend Payables | N/A | 1,159,000.00 | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | 9,004,000.00 | N/A | 15,902,000.00 | N/A | 14,628,000.00 |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Contracts With Customers | 93,449,000.00 | 127,970,000.00 | 136,971,000.00 |
| Other Income | 4,374,000.00 | 3,078,000.00 | 694,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -903,000.00 | -2,993,000.00 | -196,000.00 |
| Raw Materials And Consumables Used | 2,034,000.00 | 6,878,000.00 | 5,376,000.00 |
| Employee Benefits Expense | 34,564,000.00 | 46,781,000.00 | 59,185,000.00 |
| Depreciation And Amortisation Expense | 2,639,000.00 | 3,191,000.00 | 5,021,000.00 |
| Profit Loss From Operating Activities | 42,793,000.00 | 58,432,000.00 | 36,474,000.00 |
| Finance Income | 1,744,000.00 | 1,545,000.00 | 6,352,000.00 |
| Finance Costs | 2,128,000.00 | 975,000.00 | N/A |
| Profit Loss Before Tax | 42,409,000.00 | -59,002,000.00 | -42,142,000.00 |
| Income Tax Expense Continuing Operations | 33,143,000.00 | -12,621,000.00 | -9,283,000.00 |
| Profit Loss From Continuing Operations | 75,552,000.00 | 46,380,000.00 | N/A |
| Profit Loss From Discontinued Operations | 9,356,000.00 | N/A | N/A |
| Profit (loss) | 84,908,000.00 | 46,380,000.00 | 32,860,000.00 |
| Profit Loss Attributable To Owners Of Parent | 83,119,000.00 | 46,380,000.00 | N/A |
| Profit Loss Attributable To Noncontrolling Interests | 1,789,000.00 | 0.00 | N/A |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 | 02.01.2022 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | 84,908,000.00 | 46,380,000.00 | 32,860,000.00 | N/A |
| Adjustments For Decrease Increase In Inventories | N/A | 1,932,000.00 | 2,993,000.00 | 196,000.00 | N/A |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | N/A | 9,207,000.00 | 1,476,000.00 | N/A |
| Adjustments For Depreciation And Amortisation Expense | N/A | 9,954,000.00 | 3,191,000.00 | N/A | N/A |
| Adjustments For Sharebased Payments | N/A | 848,000.00 | 1,238,000.00 | 5,432,000.00 | N/A |
| Adjustments For Fair Value Gains Losses | N/A | N/A | -40,000.00 | N/A | N/A |
| Cash Flows From Used In Operating Activities | N/A | 46,739,000.00 | 74,970,000.00 | 58,094,000.00 | N/A |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 66,759,000.00 | 29,000.00 | N/A | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 1,912,000.00 | 10,035,000.00 | 4,791,000.00 | N/A |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | N/A | 1,563,000.00 | 7,641,000.00 | N/A |
| Other Inflows Outflows Of Cash Classified As Investing Activities | N/A | 4,000.00 | 5,000.00 | N/A | N/A |
| Cash Flows From Used In Investing Activities | N/A | 64,851,000.00 | 11,564,000.00 | 12,432,000.00 | N/A |
| Proceeds From Issuing Shares | N/A | N/A | 1,600,000.00 | 1,600,000.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,074,000.00 | 2,202,000.00 | 3,025,000.00 | N/A |
| Interest Paid Classified As Financing Activities | N/A | N/A | 694,000.00 | 499,000.00 | N/A |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | N/A | 703,000.00 | N/A | N/A |
| Cash Flows From Used In Financing Activities | N/A | -3,074,000.00 | 3,160,000.00 | 1,924,000.00 | N/A |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 108,516,000.00 | 60,246,000.00 | 43,738,000.00 | N/A |
| Cash and cash equivalents | 31,662,000.00 | 140,178,000.00 | 200,424,000.00 | 244,161,000.00 | 200,424,000.00 |
Please note that some sums might not add up.
NO0010014632
LEI5967007LIEEXZXGR7K47
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.